# Pearlium®/Effecti-Cal®, a Novel Formulation of Calcium, Vitamin D and Minerals for Prevention of Postmenopausal Bone Loss

> **NCT04609189** · PHASE4 · COMPLETED · sponsor: **University of Alberta** · enrollment: 97 (actual)

## Conditions studied

- Osteoporosis, Postmenopausal

## Interventions

- **DRUG:** Pearlium/EffectiCal
- **DRUG:** Calcium carbonate/vitamin D3

## Key facts

- **NCT ID:** NCT04609189
- **Lead sponsor:** University of Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-12
- **Primary completion:** 2014-05-02
- **Final completion:** 2014-05-02
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2023-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04609189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04609189, "Pearlium®/Effecti-Cal®, a Novel Formulation of Calcium, Vitamin D and Minerals for Prevention of Postmenopausal Bone Loss". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04609189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*